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Objective/background: Specific chromosomal translocations are found in human leukemias
and lymphomas. These translocations are closely related to particular histological and immuno-
logical phenotypes. In Burkitt’s lymphoma, translocation t(8;14)(q24;q32), which involves the
c-myc gene (8q24) and the immunoglobulin heavy-chain (IgH) locus (14q32), accounts for
90–95% of all chromosomal translocations. This translocation can be found in 2–5% of diffuse
large B-cell lymphoma (DLBCL). Long-distance polymerase chain reaction (LD-PCR) assays,
which can identify oncogene/Ig gene rearrangement, can detect these fusion genes. The objec-
tive of this study was to detect t(8;14) c-myc/IgH gene rearrangement by LD-PCR in patients
with DLBCL.
Methods: In this study, 54 DLBCL cases were tested by LD-PCR with specific primers. LD-PCR
was used for two breakpoints in both the IgH gene (joining region and c switch region) and
the myc gene (Exons 2 and 3).
142 A. Kiaei et al.Results: As much as 1.85% of the samples were positive for the c constant region and Exon 2 of
the myc gene.
Conclusion: LD-PCR can be used for the detection of t(8;14) c-myc/IgH gene rearrangement in
patients with DLBCL.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Non-Hodgkin’s lymphoma (NHL) is the eighthmost commonly
diagnosed cancer in men and the eleventh in women [1]. The
diffuse large B-cell lymphoma (DLBCL) type is the most com-
mon histological subtype of NHL. Although the treatment
options for different subtypes of NHL are almost similar,
DLBCL includes a heterogeneous group of NHL with different
prognoses and molecular and clinical characteristics [2].
Moreover, other mature B-cell neoplasms with aggressive
behavior exhibit changes in the myc gene [3]. Most patients
with Burkitt’s lymphomas and some of those with DLBCL dis-
play chromosomal translocation t(8;14)(q24;q32) accompa-
nied by juxtaposition of the myc gene with enhancer
elements in the immunoglobulin heavy-chain (IgH) gene
locus. Approximately 3% of adult patients with B-lineage
acute lymphoblastic leukemia show such aberration [4].
As a pleiotropic transcription factor, myc contributes to
cellular development. It not only regulates target genes
related to growth and proliferation directly, but also con-
trols complex networks of microRNAs and apoptosis media-
tors. Increased expression of myc is seen in 70% of all
human malignancies [5]. Recombination takes place only
at the DNA level and no fusion messenger RNA or fusion pro-
tein is generated. The positions of the chromosomal break-
points in the c-myc gene and various Ig genes are widely
distributed and these breaks have specific characteristics
in every patient [6]. Balanced chromosomal translocations
are mostly seen in mature B-cell lymphomas often involving
the Ig genes and a variety of partner genes [7]. Because the
translocated partner gene is transpositioned into the Ig
locus, it frequently becomes transcriptionally deregulated.
The frequent involvement of Ig loci in chromosomal translo-
cations indicates the remodeling of Ig genes. This remodel-
ing occurs during B-cell development due to V gene segment
assembly, somatic hypermutation, and class-switch recom-
bination [8]. Translocations occur head to head (50–50)
between the two loci of c-myc and IgH genes [5]. The enhan-
cer affects the transcription of myc when it is juxtaposed
with enhancer elements of Ig gene, resulting in myc overex-
pression (Fig. 1) [5,9].
Many techniques are used for detecting t(8;14) such as
Southern blotting [10], fluorescent in situ hybridization
[11], microarray [12], and long-distance polymerase chain
reaction (LD-PCR) [13,14]. Many traditional techniques such
as Southern blot tests have been replaced by PCR-based
methods. The advantages of PCR are the low need for
DNA, relatively fast process, and detection of abnormalities
at a very low amount [15].
To detect themyc/IgH fusion in DLBCL cases, LD-PCR and
touch-down PCR were performed. In the LD-PCR assay, PCRproducts ranging from 1 kb to 10 kb are amplified with two
forward primers specific for myc Exons 2 and 3 combined,
in different reactions, with two reverse primers for the
IgH locus IGHG constant (Cc) and IGHJ joining (JH) regions.
The touch-down PCR assay was also used for the detection
of t(8;14)(q24;q32).
Materials and methods
Patients
In this investigation, we analyzed 54 cases of suspected lym-
phomas collected from the Department of Pathology, Can-
cer Institute of Imam Khomeini Hospital, Tehran, Iran, and
Imam Reza Hospital, Tabriz, Iran, between November 2008
and August 2011. We used formalin-fixed, paraffin-
embedded (FFPE) blocks. The pathological board re-
evaluated all the samples and confirmed the diagnosis
according to the World Health Organization classification
criteria [16].
Cell lines
The human BL cell lines, RAJI (IGHG breakpoint) and DG-75
(IGHJ breakpoint), were purchased from the cell bank of
Pasteur Institute of Iran (Tehran, Iran) and maintained in
Roswell Park Memorial Institute-1,640 medium with 10%
fetal calf serum. The genomic DNA, which was used as pos-
itive control in the PCRs, was then isolated from cultured
cell lines.
Template DNA extraction
From each FFPE tissue, 4- or 5-lm sections were obtained,
and transferred into sterile containers and stored at room
temperature until their use in DNA extraction. DNA was
extracted from the FFPE specimens using the FFPE DNA
extraction kit as described by the manufacturer (Quick
Extract FFPE DNA Extraction; Epicentre, Madison, WI, USA).
To evaluate the quality and quantity of the extracted
DNA [15], it was amplified by PCR and UV spectrophotome-
try at 260/280 nm using the NanoDrop ND-1,000 spectropho-
tometer (NanoDrop Technology, Wilmington, DE, USA). The
average concentration of the DNA samples was 155 ng/lL
(range 120–560 ng/lL) and its OD260/280 ratio was 1.87.
Primers
To detect the rearrangement involving the c-myc gene on
Chromosome 8q24 and the IgH locus on Chromosome
Fig. 1 Positions of c-myc/IgH breakpoints in DLBCL and detection by LD-PCR. (A) Map of the human c-myc gene on Chromosome 8;
(B) the IgH locus on Chromosome 14. (C) Prototypical c-myc/IgH fusion gene in DLBCL showing position breakpoints, and forward and
reverse primers that are used for LD-PCR. LD-PCR performed for the JH and c constant regions. Note. bp = base pair; DLBCL = diffuse
large B-cell lymphoma; LD-PCR = long-distance polymerase chain reaction.
c-myc/IgH gene rearrangement 14314q32, two primers for the c-myc gene and two primers for
the IgH locus were combined. One primer for the IGHG con-
stant region (Cc) and another one for IGHJ of the joining
region (JH) were used (Table 1).
Long-distance polymerase chain reaction
LD-PCR refers to the amplification of DNA lengths that can-
not typically be amplified using routine PCR methods or
reagents. For simple DNA templates, polymerases optimizedfor long-range PCR can amplify 30 kb. Each reaction mix-
ture (25 lL) contained 300 ng of DNA genome, 10 pM down-
stream and upstream primers, 500 lm of each deoxyribose
nucleoside triphosphate, 10 buffer with 4 mM MgCl2, and
2 units of KBC Extend long polymerase enzyme mix as indi-
cated in the KBC Extend long PCR kit (Kawsar Biotech Com-
pany, Tehran, Iran).
LD-PCR was performed in two steps. In the first step, the
reaction condition was as follows: an initial denaturation at
94 C for 4 min followed by 15 cycles of denaturation at 94 
Table 1 Primers used for LD-PCR.
FORWARD REVERSE
MYC/M6: jH:
5’ACAGTCCTGGATGATGATGTTTTTGATGAAGGTCT3’ 5’CTTACCTGAGGAGACGGTGACCGTGGTCCC3’
MYC/M9: C:
5’GAGATCCTCTGGGGTTTGCGAGATAACCCATGG3 5’GGTCACCACGCTGCTGAGGGAGTAGAGT3’
144 A. Kiaei et al.C for 20 s, annealing at 60 C for 50 s, extension at 68 C for
4 min, and a final extension for 10 min at 68 C. In the sec-
ond step, the reaction condition was as follows: an initial
denaturation at 94 C for 4 min followed by 12 cycles of
denaturation at 94 C for 10 s, annealing at 65 C for 30 s,
extension at 68 C for 4 min with gradual increments of
the extension time (20 s/cycle), and a final extension for
10 min at 68 C.
PCR products were analyzed by agarose gel electrophore-
sis (0.8% agarose in Tris base–acetic acid–EDTA buffer
stained with ethidium bromide) and visualized under a UV
transilluminator.
Results
Based on the structure of the genes involved in the t(8;14)
(q24;q32) translocation, we selected a limited number of
primers bracketing the breakpoints and specific for Exon 2
of the myc gene and for the joining and constant regions
of the IgH gene. In the PCRs, an antisense primer in myc
Exon 2 (myc/M6) was combined with an antisense primer
in the CH1 exons of IGHG or in the sixth joining segment
of IGHJ. Each investigation included two positive and nega-
tive controls. PCR conditions were optimized to fit a set of
primers for reproducing the translocation. Primers and
reaction conditions were first tested in two Burkitt’s cellFig. 2 Ethidium bromide-stained gel electrophoresis of long-
distance polymerase chain reaction. L, C, and N, respectively,
are ladder, positive control (RAJI cell line), and negative
control. S29–S16 are samples showing the myc/IgH transloca-
tion in the c breakpoint. The size of the product is 7,600 bp.
Others were negative for this translocation. Note. bp = base
pair; IgH = immunoglobulin heavy-chain locus.lines with cytogenetically proven t(8;14), using the same
myc-specific primer in different reactions in combination
with each primer recognizing a selected IgH region.
We obtained a PCR product with sizes of 1.5 kb and
7.6 kb in DG75 and RAJI cell lines, respectively. DG75 cells
were positive for the JH breakpoint with the primer specific
for the JH region and RAJI cells were positive for the Cc
breakpoint when using the Cc primer. The LD-PCR was per-
formed for 54 cases to detect t(8;14). One patient (a 55-
year-old man) was positive for the myc/M6 and Cc primer
pair (Fig. 2). The 53 LD-PCR-negative patients were tested
with the myc-9 primer (positioned in Intron 3) in combina-
tion with the Cc primer to establish whether breakpoints
could be located downstream of Exon 2 in the c-myc gene.
The results showed all of them to be negative for these
breakpoints. Existence of a PCR product was investigated
in the cases using LD-PCR for the myc-6 and JH primer pair.
However, none of them showed any PCR product. Patients
negative for the joining region (JH) breakpoint were re-
examined with touch-down PCR. No PCR product was pro-
duced with this method either.
Discussion
DLBCL is a heterogeneous disease comprising 30% of adult
NHLs. It has different subtypes and clinical outcomes [17].
Considering the curable nature of the disease by suitable
treatment, it is crucial to identify infiltration of lymphoma-
tous for determination of the state of the disease accurately
as well as evaluation of the therapy [18]. Most DLBCLs are
accurately diagnosed using immunohistochemistry or flow
cytometric immunophenotyping. However, diagnosis
becomes complicated in 5–10% of the patients [19,20].
In these patients, molecular gene rearrangement studies
have been found to be useful as a complementary diagnostic
tool [21]. The t(8;14) translocation is common in Burkitt’s
lymphoma and a subset of DLBCL [4]. The myc oncogene
on Chromosome 8 and the IgH locus on Chromosome 14
are involved in this translocation. The c-myc gene consists
of three exons, among which Exons 2 and 3 include the cod-
ing sequence for the c-myc protein. Because of sequences
that block transcriptional elongation, Exon 1 encodes an
untranslated sequence acting as a negative regulatory
sequence. The negative regulatory Exon 1 and Intron 1
sequences are removed in some lymphomas because the t
(8:14) breakpoints tend to be in the first intron [22].
The Ig-enhancer elements that contribute to c-myc dys-
regulation specifically stimulate transcription in B cells nor-
mally. The IgH El or Ea enhancer in the c-myc coding
sequences can potentially induce B-cell tumors, suggesting
that in tumors with translocation t(8;14), IgH elements
per se might increase oncogenic levels of c-myc expression
c-myc/IgH gene rearrangement 145[23]. The LD-PCR can identify t(8;14) at the genomic level,
and is therefore useful for this translocation considering
that it does not produce a fusion gene [24]. Moreover, it
can be applied to translocations in which the DNA sequences
of the regions immediately adjacent to the breakpoint have
not yet been identified. The other advantage is that ampli-
fied fragments have sequences unique to individual
patients. Thus, this PCR technique could be applied to ana-
lyze translocations in leukemia. PCR using DNA is consider-
ably easier than RT-PCR, which requires RNA isolation and
complementary DNA synthesis.
DLBCL of B-cell phenotype comprises 30–40% of adult
NHL [25] and is a good candidate for such an aggressive
treatment. Therefore, sensitive genetic markers of this par-
ticular lymphoma subtype are required for assessing mini-
mal residual disease [17]. Translocations involving myc are
also found in other hematological malignancies in addition
to Burkitt’s lymphoma, most importantly in the subsets of
DLBCL. In this tumor, a chromosomal translocation at the
myc locus shows a more aggressive tumor phenotype and a
lower survival rate [26]. Two to five percent of DLBCLs are
affected by the t(8;14) translocation in several breakpoints
in themyc (Exons 2 and 3) and IgH genes (Jh, Cl, Cc, Cd, Ca,
and Ce). We performed LD-PCR only for the JH region and
one constant region (c) with Exon 2 of the myc gene in 54
samples. In lymphoma patients with JH break, the positions
of the IgH l enhancer affects transcription of the myc gene.
The breaks in the IgH gene occur during attempted V(D)J
recombination, leading to the juxtaposition of the IgH
enhancer with c-myc. However, with respect to the c switch
region, the breakpoints in the IgH gene occur during
attempted Ig switching, leading to the juxtaposition of 30
IgH-enhancer elements (such as Ea) with sequences of c-
myc. These enhancers affectmyc’s promoter and expression
of myc. Only one patient was positive (1.85%) for the c
breakpoint. However, in negative samples, it is suggested
that translocation happened in other breakpoints. DLBCL
can affect any age group, but mostly occurs in elderly
patients (normally in people in the mid-60s). Therefore,
LD-PCR can be used for the detection of t(8;14) c-myc/IgH
gene rearrangement in patients with DLBCL.
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